Thalidomide and the IMiD immunomodulatory drugs, lenalidomide and pomalidomide, are widely used in the treatment of multiple myeloma (MM), del(5q) myelodysplastic syndromes and other hematologic malignancies, including mantle cell lymphoma. Ito *et al.*^[@bib1]^ recently identified cereblon as a key target of thalidomide. Subsequent studies confirmed cereblon to be a common target for lenalidomide and pomalidomide, and established its essential role in mediating anticancer and immunomodulatory effects of these drugs.^[@bib2],\ [@bib3]^ Cereblon is encoded by the *CRBN* gene on chromosome 3 containing 11 exons, and the fully spliced transcript produces a 51-kDa protein. Cereblon is a component of the cullin ring E3 ubiquitin ligase complex (CRL4^CRBN^) that also contains DNA damage-binding protein 1 (DDB1), cullin (Cul) 4a and regulator of cullins (Roc) 1.^[@bib1]^ E3 ligases attach ubiquitin moieties to specific substrate proteins in the cell that can mark them for proteasomal degradation. The putative role of cereblon within the E3 ligase complex is that of a substrate receptor.

With the discovery of cereblon, as a target of IMiD therapy, there has been considerable interest in defining whether expression of cereblon protein or the presence of CRBN mutations will impact clinical responses to these drugs.^[@bib2],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib7]^ There are limited available data on *CRBN* gene mutation in the literature. Originally, a nonsense mutation (R419X) of CRBN was described to be associated with autosomal recessive non-syndromic mental retardation.^[@bib8]^ However, the functional link between the mutation in CRBN and the onset of mental retardation has not been demonstrated. Sequencing analyses of CRBN in MM cells from patients identified a truncating mutation (Q99X) and a point mutation (R283K) in 1 of 30 MM patients.^[@bib9]^ In addition, an A/G polymorphism has been identified at −29 nucleotide from the transcriptional start site of the CRBN transcript.^[@bib10]^ So far, mutations in other components of the CRL4 E3 ligase complex (DDB1, Cul4a or Roc1) in MM cell lines or patients have not been described in the limited genome-wide sequencing of MM patients.^[@bib11]^

Here, we focused on sequencing the exons of *CRBN* with a goal of identifying missense or nonsense mutations with likely functional and clinical consequence. We analyzed IMiD-sensitive, intrinsically IMiD-resistant, as well as isogenic-sensitive or acquired lenalidomide- and/or pomalidomide-resistant MM cell lines. In addition, 90 MM patient samples, including those from 36 lenalidomide-resistant patients, were evaluated for the presence of *CRBN* mutations. As shown in [Table 1](#tbl1){ref-type="table"}, we found that the vast majority of IMiD-sensitive cell lines harbored the wild-type *CRBN* gene sequence. Also, none of the three intrinsically resistant cell lines (LP1, RPMI 8226 or JJN3) carried any mutation within the *CRBN* exons. As described previously, all three cell lines express high levels of cereblon transcript and protein.^[@bib12]^ Thus, the lack of mutation in the *CRBN* gene strongly suggests the existence of a cereblon-independent mechanism(s) of intrinsic resistance to IMiD drugs in the LP1, RPMI 8226 and JJN3 cell lines. In contrast, a heterozygous *CRBN* mutation (D249Y) was detected in the lenalidomide-resistant ANBL-6 cell line, while its sensitive parental line did not harbor the mutation. The location of the mutation suggests that it may impact the binding of cereblon to the drug or interacting partner DDB1. However, it is not clear whether the resistant phenotype in the lenalidomide-resistant ANBL-6 cell line is a direct result of the *CRBN* mutation alone and therefore it requires further evaluation. One copy of *CRBN* gene was shown to be deleted in the MM1S and MM1S.R MM cell lines.^[@bib2]^ However, in our sequencing of the *CRBN* gene in these cell lines, we did not find any missense mutation or single-nucleotide variations (SNVs). SNVs, as opposed to missense or nonsense mutations, are synonymous substitutions of nucleotides that do not change the amino acid at a given codon. In all, we found two SNVs in the KMS-12-BM (rs17027638) and OPM-2 cell lines, respectively. The SNV in OPM-2 has not been described in the public database. Among the isogenic sensitive and resistant pairs of cell lines, no new mutation or polymorphic changes were detected.

We next sequenced the *CRBN* gene from 90 MM patients. All samples collected in this study followed institutional procedures for ethical guidelines and informed consent for the analysis. Samples used for the sequencing analysis were either CD138^+^ cells isolated from bone marrow aspirates (*n*=36) or bone marrow mononuclear cells (BMMC; *n*=54) with a plasma cell content of at least 20%. The patients were further divided according to disease status: newly diagnosed (*n*=24); relapsed/refractory (*n*=30, 19 of whom were heavily pretreated with multiple regimens that included lenalidomide); or relapsed and/or refractory with lenalidomide resistance (*n*=36; clinical criteria for resistance were progression within two cycles or relapse within 6 months of completing the last line of an IMiD-based regimen). In the 24 newly diagnosed patients, two SNVs were detected, and in the 66 relapsed and refractory patients two SNVs were also detected: one of the SNVs was identified in four cases at position 735 (T\>C; Y245Y) that was seen previously in the cell lines and the other SNV was found once at 219 (C\>T; H73H). Both SNVs have been previously described in public databases (<http://www.ncbi.nlm.nih.gov/projects/SNP/>). Strikingly, we did not find any mutation in the *CRBN* gene in any of the lenalidomide-resistant patient samples.

As DDB1 interaction with cereblon is critical for the E3 ligase function, the *DDB1* gene may potentially harbor mutations of clinical significance. So, we extended our sequencing analysis to *DDB1* to search for the presence of mutations in MM cell lines and patients. Of more than 20 cell lines tested, only a single *DDB1* heterozygous mutation (E303D) was identified in the ANBL-6 parental cell line ([Table 1](#tbl1){ref-type="table"}). There is no known functional consequence of this mutation, as ANBL-6 is sensitive to lenalidomide. In the 54 BMMC patient samples tested from newly diagnosed and relapsed and refractory patients, two different SNVs were detected: One of the SNVs occurred six times at nucleotide position 153 (C\>T; P51P) and the other once at nucleotide position 939 (C\>T; C313C). Both SNVs have been described in the dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP/>).

There are a number of implications of the sequencing analyses presented here. Although the number of cell lines and patients tested is limited, our findings suggest that incidence of *CRBN* and *DDB1* gene mutations in MM cell lines and patients are rare and will have a limited impact on defining resistance to IMiD therapy. In the three intrinsically IMiD-resistant cell lines that clearly express detectable levels of cereblon, the absence of *CRBN* and *DDB1* mutations suggest that potential cereblon-independent mechanisms of resistance exist. We did, however, detect a mutation in the lenalidomide-resistant ANBL-6 cell line. Thus, the development of lenalidomide resistance in the ANBL-6 cell line may be linked to a *CRBN* mutation and provides the proof of principle that resistance to IMiD exposure could arise by a mutation within the *CRBN* gene. Finally, unlike for ATP-dependent kinase inhibitors, where there is precedence for development of drug resistance due to selection of mutant forms of the drug targets, this does not appear to be a common mechanism for IMiD therapy.

It has been shown by us and others that cereblon levels (measured by gene expression or protein assays) are lower compared with pretreatment levels when cell lines or patients become resistant to lenalidomide or pomalidomide.^[@bib2],\ [@bib13]^ It is likely that epigenetic, transcriptional and/or posttranscriptional mechanisms---rather than *CRBN* mutation---are predominantly involved in the development of CRBN-dependent mechanisms of resistance to IMiD-based therapy. Therapeutic intervention to overcome IMiD resistance may have to address the consequences arising from these alternative mechanisms.
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###### Summary of mutations and SNVs in *CRBN* and *DDB1* in MM cell lines and patients

  *IMiD-sensitive MM cell lines*                         CRBN *nucleotide position and change*                *CRBN amino-acid position and change*   DDB1 *nucleotide position and change*                  *DDB1 amino-acid position and change*
  ------------------------------------------------------ ---------------------------------------------------- --------------------------------------- ------------------------------------------------------ -----------------------------------------------
  H929 parental, U266, EJM, SKMM2                        None                                                                                         None                                                    
  OPM-2                                                  G1209A silent heterozygous                           T403T                                   None                                                    
  KMS-12-BM parental                                     T735C silent homozygous                              Y245Y                                   None                                                    
  *Intrinsic IMiD-resistant MM cell lines*                                                                                                                                                                   
   LP1                                                   None                                                                                         None                                                    
   RPMI 8226                                             None                                                                                         None                                                    
   JJN3                                                  None                                                                                         None                                                    
  *Paired sensitive and acquired resistant cell lines*                                                                                                                                                       
   H929 sensitive control                                None                                                                                         None                                                    
   H929 4 resistant clones                               None                                                                                         None                                                    
   KMS-12-BM sensitive control                           T735C silent homozygous                              Y245Y                                   None                                                    
   KMS-12-BM LEN-resistant                               T735C silent homozygous                              Y245Y                                   None                                                    
   KMS-12-BM POM-resistant                               T735C silent homozygous                              Y245Y                                   None                                                    
   MM1S sensitive                                        None                                                                                         None                                                    
   MM1S/R10R LEN-resistant                               None                                                                                         None                                                    
   ANBL-6 sensitive                                      None                                                                                         A909T heterozygous                                     E303D
                                                         None                                                                                         C153T silent heterozygous                              P51P (rs2230356)
   ANBL-6 LEN-resistant                                  G745T heterozygous                                   D249Y                                   A909T heterozygous                                     E303D
                                                         None                                                                                         C153T silent heterozygous                              P51P (rs2230356)
  *Patient samples (90)*                                                                                                                                                                                     
   Newly diagnosed (24)                                  T735C silent homozygous, C219T silent heterozygous   2 × Y245Y (rs17027638), 1 × H73H        C153T silent heterozygous, C939T silent heterozygous   2 × P51P (rs2230356), 1 × C313C (rs150106100)
   RRMM (30)                                             T735C silent homozygous                              2 × Y245Y (rs17027638)                  C153T silent heterozygous                              4 × P51P (rs2230356)
   LEN-resistant RRMM (36)                               None                                                                                         None                                                    

Abbreviations: CRBN, cereblon; DDB1, DNA damage-binding protein 1; IMiD, immunomodulatory drug; LEN, lenalidomide; MM, multiple myeloma; POM, pomalidomide; RRMM, relapsed/refractory multiple myeloma; SNV, single-nucleotide variation.
